CVRx / Barostim
Baroreflex activation in selected heart failure
Commercial; functional evidence and ongoing outcomes development
Evidence mapping, referral research, responder studies
INNOVATION OBSERVATORY · 29 SEPTEMBER 2026 SNAPSHOT
A landscape of interventions, sensing, workflows, and the gaps between them.
Direct participants, adjacent platforms, and potential partners. Inclusion is not endorsement or a product-quality ranking.
Baroreflex activation in selected heart failure
Commercial; functional evidence and ongoing outcomes development
Evidence mapping, referral research, responder studies
Ultrasound renal denervation
FDA-approved system; market access varies by country and payer
Hypertension pathway and brain-health evidence integration
Renal denervation and insertable rhythm monitoring
Distinct therapeutic and diagnostic product lines
Connect neural BP intervention and rhythm workflows without conflating products
Paired VNS with stroke rehabilitation
Formerly MicroTransponder; FDA-approved defined use; public listing in 2026
Rehabilitation pathway and outcome literacy
Neuroimmune modulation for rheumatoid arthritis
FDA-approved specified RA use in 2025
Adjacent platform precedent; not a direct cardiac competitor
Noninvasive vagus stimulation in neurocritical care
Company-reported seed funding and development program; investigational
Emerging stroke/inflammation research watchlist
TRPC-channel drug development across brain and cardiac injury
Early clinical program; company-reported Phase IIa MI study activity
Shared injury biology watchlist, not a neural device or proven treatment
Ambulatory ECG analysis and clinical workflow
Cardiac rhythm evidence; ECG is not a nerve recording
Rhythm and post-stroke monitoring evidence
Wearable multiparameter monitoring
Acquisition by iRhythm announced; closing not verified as of cutoff
Hospital-to-home multimodal workflow watchlist
Insertable cardiac monitoring
Cardiac rhythm monitoring rather than direct brain sensing
Longitudinal rhythm pathway
Mobile cardiac outpatient telemetry
Monitoring service; economic modeling is not randomized clinical benefit
Monitoring workflow and evidence comparison
Consumer and professional ECG products
Product-specific clearances; capabilities differ across devices
Accessible rhythm literacy and product comparison
Consumer physiological monitoring and selected regulated features
Hypertension notification is not a blood-pressure reading or diagnosis
Explain the detection-to-confirmation gap
Seizure-alert and research wearable platforms
Peripheral signals rather than EEG; alerting does not establish SUDEP prevention
Cross-condition signal literacy and study infrastructure
Cardiac intervention portfolio and announced Penumbra transaction
Proposed portfolio expansion is not a completed acquisition
Established firms increasingly span vascular territories
Neurovascular and peripheral vascular intervention
Transaction status must remain current and explicit
Acute treatment workflow differs from chronic risk sensing
Imaging and clinical workflow software across neurovascular care
Product-specific clearances; not general population stroke prediction
Benchmark time-sensitive workflow integration
Neurovascular imaging and care-coordination platform
The cited brochure documents offerings at publication, not an exhaustive 2026 product inventory
Benchmark multidisciplinary coordination